Clinical Commissioning Policy: Teriparatide for the treatment of osteogenesis imperfecta (Adults)

Reference: NHS England: 16002/P
**NHS England INFORMATION READER BOX**

<table>
<thead>
<tr>
<th>Directorate</th>
<th>Operations and Information Trans. &amp; Corp. Ops.</th>
<th>Specialised Commissioning Commissioning Strategy</th>
</tr>
</thead>
</table>

**Publications Gateway Reference:** 05527s

<table>
<thead>
<tr>
<th>Document Purpose</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Name</td>
<td>Clinical Commissioning Policy 16002/P</td>
</tr>
<tr>
<td>Author</td>
<td>Specialised Commissioning Team</td>
</tr>
<tr>
<td>Publication Date</td>
<td>13 July 2016</td>
</tr>
<tr>
<td>Target Audience</td>
<td>CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs</td>
</tr>
</tbody>
</table>

**Additional Circulation List**

<table>
<thead>
<tr>
<th>Description</th>
<th>Not Routinely Commissioned - NHS England will not routinely commission this specialised treatment in accordance with the criteria described in this policy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross Reference</td>
<td>This document is part of a suite of policies with Gateway Reference 05527s.</td>
</tr>
<tr>
<td>Superseded Docs (if applicable)</td>
<td>N/A</td>
</tr>
<tr>
<td>Action Required</td>
<td>N/A</td>
</tr>
<tr>
<td>Timing / Deadlines (if applicable)</td>
<td>N/A</td>
</tr>
<tr>
<td>Contact Details for further information</td>
<td><a href="mailto:england.specialisedcommissioning@nhs.net">england.specialisedcommissioning@nhs.net</a></td>
</tr>
</tbody>
</table>

**Document Status**

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.
Clinical Commissioning Policy: Teriparatide for the treatment of osteogenesis imperfecta (Adults)

First published: July 2016

Prepared by NHS England Specialised Services Clinical Reference Group for Specialised Endocrinology

Published by NHS England, in electronic format only.
## Contents

1. Introduction .................................................................................................................. 7
2. Definitions ..................................................................................................................... 7
3. Aims and Objectives .................................................................................................... 8
4. Epidemiology and Needs Assessment ........................................................................ 8
5. Evidence Base ............................................................................................................. 8
6. Documents which have informed this Policy ............................................................. 12
7. Date of Review ............................................................................................................ 12
8. References .................................................................................................................... 13
Policy Statement
NHS England will not routinely commission teriparatide for the treatment of osteogenesis imperfecta (adults) in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources. This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement
Promoting equality and addressing health inequalities are at the heart of NHS England’s values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

Plain Language Summary
About osteogenesis imperfecta
Osteogenesis imperfecta (OI) is a group of genetic disorders that are inherited.

- They mainly affect the bones, making the skeleton weak.
- This makes the bones break easily – for this reason it is also called ‘brittle bone disease’.

The risk of fractures is high in childhood – and this gets less following puberty. However, the risk of fracture still remains high compared to people with normal bones.
About the new treatment
Teriparatide is a medicine which stimulates new bone to form. This has been shown to make fractures less likely in patients with a different condition, osteoporosis (NICE Technology Appraisal Guidance TA161, 2008).

What we have decided
NHS England has carefully reviewed the evidence to treat osteogenesis imperfecta (brittle bone disease) with teriparatide in adults. We have concluded that there is not enough evidence to make the treatment available at this time.
1 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to not routinely commission teriparatide for adults with osteogenesis imperfecta.

Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the bones causing weakness of the skeleton leading to easy fractures.

Teriparatide stimulates bone formation, and has been shown to reduce fracture risk in osteoporosis. All the other established treatments for osteogenesis imperfecta work by inhibition of bone resorption. Teriparatide has been proposed as a treatment to improve bone density and reduce the risk of fracture in patients with increased bone turnover, as an alternative to conventional treatments (such as bisphosphonates).

2 Definitions

Osteogenesis imperfecta (OI) is an inherited disorder in which there is an abnormality of production of type I collagen. This causes weakness of the skeleton, leading to easy fracture and the alternative name of "brittle bone disease". The majority of affected individuals will suffer from a significant fracture burden during infancy and childhood; the fracture risk declines following puberty but still remains significantly raised in adults compared to individuals with normal bones.

Patients with osteogenesis imperfecta are at significantly increased risk of fracture, suffer skeletal pain and in some cases disability as a result of previous fractures. In addition to bone abnormalities, patients with osteogenesis imperfecta often experience hypermobility syndrome, cardiac abnormalities, dental problems, and deafness.

The characteristic features of OI vary greatly from person to person, even among people with the same type of OI, and even within the same family. Not all characteristics are evident in each case. The majority of cases of OI (possibly 85-
90%) are caused by a dominant mutation in a gene coding for type I collagen (Types I, II, III, and IV). Types VII and VIII are newly identified forms that are inherited in a recessive manner. The genes causing these two types have been identified. Types V and VI do not have a type 1 collagen mutation, but the genes causing them have not yet been identified.

Although the types of OI are clearly defined, the treatment approach for Type I and Type IV are similar.

Teriparatide is a recombinant human version of the active portion of the parathyroid hormone molecule and, as an anabolic agent, it stimulates new formation of bone and increases resistance to fracture. Unlike any of the other treatments for osteogenesis imperfecta, teriparatide works by stimulation of bone formation. All the other established treatments work by inhibition of bone resorption.

3 Aims and Objectives

This policy aims to define NHS England commissioning position in teriparatide as part of the treatment pathway for adult patients with osteogenesis imperfecta.

The objectives are to ensure evidence based commissioning in the use of teriparatide for the treatment of adults with osteogenesis imperfecta.

4 Epidemiology and Needs Assessment

It is estimated that osteogenesis imperfecta is present in one in every 15,000 people (Brittle Bone Society, 2015), with approximately two thirds of affected people having the mildest form of the condition (type I osteogenesis imperfecta).

5 Evidence Base

NHS England has concluded that there is not sufficient evidence to support a proposal for the routine commissioning of teriparatide for osteogenesis imperfecta (OI) in adult patients.
There is evidence that teriparatide stimulates bone formation, and has been shown to reduce fracture risk in osteoporosis (NICE Technology Appraisal Guidance TA161, 2008).

**Summary**

Osteogenesis Imperfecta (OI) is a rare genetic disease characterised by increased bone fragility resulting in frequent fractures and deformities. OI has been classified into eight types.

Bisphosphonates (BPs) are antiresorptive compounds widely used to treat patients with OI and are considered the prevailing standard of care for moderate to severe forms of the disease. Teriparatide (synthetic form of human parathyroid hormone) is a bone anabolic therapy that is used selectively in management of osteoporosis.

The review of current evidence for teriparatide was undertaken to:
- Determine whether it is a clinically effective treatment in adults with osteogenesis imperfecta (OI) compared to conventional therapies
- Assess whether the drug is more effective than conventional therapies in achieving critical and important patient outcomes
- Establish whether the drug is more effective as a first line treatment than as a second line treatment
- Determine the drug’s cost effectiveness and safety in treating adults with OI

The literature on this topic was sparse with systematic search identifying only three relevant studies. These include one randomised control trial funded by Eli Lilly, one case series and a single case report. None of the studies directly compared the clinical or cost effectiveness of teriparatide with other conventional therapies for OI. The randomised control trial evaluated the clinical effectiveness of teriparatide compared to a placebo group. The prospective case series described the effects of teriparatide on bone turnover markers in thirteen postmenopausal women with Type I OI. The case report was not included in this summary as it reports on changes in bone turnover markers and bone fracture healing in a single patient on teriparatide.
In summary, the current limited evidence from one RCT and one small retrospective study indicates that teriparatide increases bone density and bone strength in adults with mild forms of OI (Type I). It is associated with good response in procollagen type 1 N-terminal-propeptide (P1NP) and other markers of bone turnover, particularly for Type I OI only. There is inconclusive and very low level evidence on reduction in fracture rates by teriparatide. No serious side-effects have been reported in the patient population subset included in the studies. There is currently no evidence on comparative clinical or cost effectiveness of teriparatide with other conventional therapies for OI. Due to lack of comparative data, this review is unable to establish whether teriparatide is more effective as first or second line treatment.

Summary of the evidence

A double-blind, randomised, placebo control trial to determine the clinical effectiveness of teriparatide in adults over 18 months of treatment was undertaken to determine the baseline change in the lumbar spinal areal bone mineral density (aBMD) between the treatment group and placebo group (Orwoll et al., 2014). The study concluded that at 18 months, change in aBMD in the teriparatide group was higher than the placebo group by:
- 5% at the total hip (p<0.001)
- 3.3% at the lumbar spine (p<0.05)
- 3.7% at the femoral neck (no statistical difference - p value not specifically stated)

A test of 3-way interaction (treatment group, time and OI type) showed that the trend in treatment response in aBMD over the course of the study was significantly different in patients with Type I OI compared to Type III/IV patients. Type I patients had significant treatment effects at 12 and 18 months (p=0.04 and p=0.002, respectively) while those with Type III/IV had no response at any time point. There were a total of 26 Type III/IV patients (14 Type III and 12 Type IV) in this sub group compared to 51 in Type 1 subgroup. This unequal distribution of subjects within subgroups could potentially impact adequate assessment of treatment effect.
Gatti et al. (2013) evaluated the clinical effectiveness of teriparatide treatment in 13 adult patients with Type I OI over an 18-month period. The study found BMD at the lumbar spine increased significantly throughout treatment by up to 3.5% (p=0.001). However, unlike Orwoll et al (2014), Gatti et al. (2013) did not find any significant changes in hip BMD (no p value specifically stated).

Eleven patients in the teriparatide treatment group (29%) and 14 in the placebo group (36%) reported fractures (odds ratio, 0.73; 95% CI, 0.28-1.90) during the randomised control trial (Orwoll et al., 2014). During the Gatti et al. (2013) study, none of the patients reported new fractures during the treatment. However, both studies had limited follow-up period (18 months) and were not powered to adequately assess the effect of teriparatide on fracture risk. Given the small number of patients, the extent to which these studies represents the actual patient population, remains a concern which was not adequately addressed in either of the trial methodologies.

Bone turnover markers, such as P1NP and bone alkaline phosphatase (bAP), are associated with bone formation whilst C-terminal telopeptide of type I collagen (serum CTX) is associated with bone resorption. The randomised trial found that P1NP levels increased rapidly with a maximum at month 12 (134.6%) in the intervention group which was significantly higher than the placebo group (p<0.001). Patients with Type I OI had more significant increases in serum P1NP (p<0.001) than those with Types III and IV (Orwoll et al., 2014). Gatti et al. (2013) reported significant (p<0.005) increase in P1NP, bAP and serum CTX in response to teriparatide treatment. The study also found positive correlation (p<0.01) between elevation of bone formation markers (P1NP and bAP) with percentage changes in dickkopf WNT signalling pathway inhibitor 1 (DKK1) which is an inhibitor of the wnt/B-catenin pathway for bone formation.

Orwoll et al. (2014) found that teriparatide was well-tolerated and there were no differences in adverse events observed between the treatment and placebo groups. Gatti et al. 2013 reported over half (n=7) reported mild nausea after injection, however this did not lead to treatment discontinuation.
In conclusion, at biochemical level, teriparatide is associated with good response in P1NP and other bone turnover markers, particularly for patients with less severe Type I OI. This response is reflected in the radiological effectiveness where teriparatide appears to increase lumbar bone density and bone strength in adults with the mild form of OI (Type I) and not in patients with Type III/IV OI. In the absence of well-designed studies to assess the actual clinically meaningful impact of this treatment such as reduction in fracture risk in target population, the clinical effectiveness of teriparatide remains inconclusive. There is currently no evidence regarding clinical or cost effectiveness of teriparatide in comparison to other conventional therapies for OI. Due to lack of comparative data, this review is also unable to establish whether teriparatide is more effective as first or second line treatment. The drug appears to be well tolerated, in the small subset of patients included in the studies.

6 Documents which have informed this Policy


7 Date of Review

This document will be reviewed when information is received which indicates that the policy requires revision.
References

Brittle Bone Society, 2015 www.brittlebone.org

Gatti, Davide; Rossini, Maurizio; Viapiana, Ombretta; Povino, Maria Rosaria; Liuzza, Saverio; Fracassi, Elena; Idolazzi, Luca; Adami, Silvano. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif. Tissue Int. 2013.
